Compound ID | 2789
Class: Antimicrobial peptide
| Details of activity: | Active against carbapenem-resistant and -susceptible Acinetobacter baumannii; no activity against other Gram-negatives (selectivity due to lipopolysaccharide transport [Lpt] protein differences affecting how they bind to the LPS); lipopolysaccharide synthesis inhibitor targeting Lpt transporter |
| Description: | Synthetic compound made as part of the macrocyclic peptidomimetics library by Tranzyme Pharma Inc. (Canada); a macrocyclic peptide |
| Institute where first reported: | Roche Pharma Research and Early Development, Immunology, Infectious Disease and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland |
| Year first mentioned: | 2024 |
| Highest developmental phase: | Preclinical |
| Development status: | Active (as of 2024) |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/129098768 |
| Guide to Pharmacology: | RO7075573 |
| Citations: |
|